Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elenbecestat placebo-controlled phase 3 study in early Alzheimer's disease
2016-004128-42Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Elenbecestat with Placebo (2 arms). Primary endpoint: Change from baseline in Clinical Dementia Rating - Sum of Boxes. Started Mar 2017; status: completed.
02
Drugs
elenbecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2016-004128-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004128-42.